STATE OF HEALTH CARE SUMMIT // AGENDA February 13, 2015 Stay tuned for updates to the agenda’s speaker roster. 8:30 AM - 9:15 AM Keynote Address: What Lies Ahead for Biotech in 2015? The day will kick off with a keynote addressing trends that are shaping the biotech industry in 2015. 9:30 AM - 10:00 AM Panel: Medical Device Innovation Drives Growth Higher This panel will investigate new therapies such as transcatheter heart valves and drug-coated balloons. Speakers: Jason McGorman, Analyst, Bloomberg Intelligence 10:00 AM - 10:30 AM Panel: Innovation in Liver Diseases: HCV and NASH The panel will discuss advances in the treatment of hepatitis C and fatty liver disease. Speakers: Keith Hoffman, V.P. Scientific Affairs, AdverseEvents Dr. Hillel Tobias, NYU Asthika Goonewardene, Senior Analyst, Bloomberg Intelligence Liz Krutoholow, Analyst, Bloomberg Intelligence 10:40 AM - 11:10 AM Panel: Investor Outlook 2015 A discussion of what investors are most interested in for 2015. Speakers: Leon Chen, Ph.D., Venture Partner, OrbiMed Andrew Hilgenbrink Director at Highland Capital Healthcare Partners Les Funtleyder, Healthcare Portfolio Manager, E Squared Asset Management Sam Fazeli, Head of Research, EMEA, Bloomberg Intelligence Asthika Goonewardene, Senior Analyst, Bloomberg Intelligence 11:10 AM - 11:40 AM Panel: Cancer Innovation The panel of key opinion leaders will discuss advances with immunotherapy and novel approaches like CAR-T in blood cancers. Speakers: Michel Sadelain, MD, PhD, Memorial Sloan Kettering, cofounder Juno Therapeutics Peter Emtage, Ph.D., Vice President, Synthetic Immunology, Intrexon Asthika Goonewardene, Senior Analyst, Bloomberg Intelligence Liz Krutoholow, Analyst, Bloomberg Intelligence 11:40-11:55 Break 11:55 AM – 12:55 PM Address: Bloomberg-BIO Joint Survey on 2015 Results of our survey of industry stakeholders and investors will be revealed. Speakers: Mark Schoenebaum, Senior Managing Director, Head of Evercore ISI's Health Care Research Team Bernard Fallon, Senior Manager, Industry Research & Event Programming, Business Development at BIO Asthika Goonewardene, Senior Analyst, Bloomberg Intelligence Liz Krutoholow, Analyst, Bloomberg Intelligence 12:55-1:10 Break 1:10 PM - 1:45 PM Panel: What's the Cost of Pricing Pressure? Drug developers have been facing pushback on the price of drugs. The panel will explore ways in which the healthcare system will deal with the rising price of novel therapies. Speakers: Dr. Robert Dubois, Chief Science Officer, National Pharmaceutical Council Michael Kuehn, Simon Kucher Partners Tanisha Carino, EVP, Life Sciences Avalere Sam Fazeli, Head of Research, EMEA, Bloomberg Intelligence Asthika Goonewardene, Senior Analyst, Bloomberg Intelligence 1:45 PM - 2:15 PM Panel: The Evolution of the U.S. Biosimilars Market Experts will clarify complexities in the regulatory pathway for biosimilars and ramifications of ongoing litigation. Speakers: Kevin M. Nelson, Partner, Duane Morris Alex Waldron, VP of Global Commercial Operations, Epirus Biopharmaceuticals Sam Fazeli, Head of Research, EMEA, Bloomberg Intelligence Aude Gerspacher, Senior Analyst, Bloomberg Intelligence 2:15 PM - 2:45 PM Panel: Will ACA Reign Supreme in 2015? A discussion of on-going challenges to the ACA and implications for the industry. Speakers: Michael Kolber, Attorney, Manatt, Phelps & Phillips, LLP Greg Nersessian, Principal at Health Management Associates Brian Rye, Healthcare Policy Analyst, Bloomberg Intelligence Jason McGorman, Analyst, Bloomberg Intelligence Aude Gerspacher, Senior Analyst, Bloomberg Intelligence 2:45 PM - 3:15 PM Discussion: M&A in 2015 Find out what the hottest areas in M&A will likely be and whether 2015 will provide another year of consolidation in the industry. Speakers: Sam Fazeli, Head of Research, EMEA, Bloomberg Intelligence